Clinical trials: B-cell Acute Lymphocytic Leukemia
B-cell Acute Lymphoblastic Leukemia, Obesity
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients with B-ALL.
- Trial name
- IDEAL2 (NCT05082519)
- Testing
- IDEAL2 Intervention
- Where
- 16 sites in United States
- Volunteers
- 240 people
- Sponsor
- Etan Orgel
Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
The safety run-in part of the study aims to evaluate the safety and tolerability of blinatumomab alternating with low-intensity chemotherapy.
- Trial name
- NCT04994717
- Testing
- Blinatumomab, Low-intensity chemotherapy regimen, SOC chemotherapy regimen
- Where
- 192 sites in United States, Australia and 30 more
- Volunteers
- 303 people
- Sponsor
- Amgen
Lymphoma, Small Intestine Cancer
Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the Pelvis
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Irinotecan may be effective in treating patients with abnormal liver or kidney function or who have received…
- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00003368
- Testing
- irinotecan hydrochloride
- Where
- 45 sites in United States
- Sponsor
- National Cancer Institute (NCI)
B Cell Lymphoma, Acute Lymphoblastic Leukemia
Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies
1. Study Title: A Study on the Efficacy and safety of Autocrine p40-Expressing CD19-Targeted Chimeric Antigen Receptor T Cells (CD19-CAR.p40-T) in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies 2.
- Conditions
- B Cell Lymphoma, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
- Trial name
- CAR-p40-T (NCT07584889)
- Testing
- CAR-T cell
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shenzhen University General Hospital
Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma
A Study of CT-RD06 Cell Injection in Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancy
A study of CT-RD06 cell injection in patients with relapsed or refractory CD19+ B-cell hematological malignancy.
- Trial name
- NCT04226989
- Testing
- CT-RD06
- Where
- China
- Volunteers
- 72 people
- Sponsor
- He Huang
Acute Leukemia, Acute Leukemia Refractory
Ex Vivo T-Cell-Depleted Haploidentical Transplantation Bridging With Chimeric Antigen Receptor T-cell Therapy and Prophylactic Memory T Cell Infusion for Acute Leukemia
CAR-T therapy has evolved as a pivotal treatment for relapsed/refractory (R/R) leukemia, demonstrating improved remission rates and manageable adverse events.
- Conditions
- Acute Leukemia, Acute Leukemia Refractory, Acute Myeloid Leukemia (AML), ALL (Acute B-Lymphoblastic Leukemia)
- Trial name
- NCT07087847
- Testing
- TCRαβ+/CD45RA+depleted haploidentical hematopoietic stem cell transplantation (haplo-HSCT)
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Ruijin Hospital
Anemia, Leukemia
Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer
RATIONALE: Darbepoetin alfa and epoetin alfa may stimulate red blood cell production and treat anemia in patients who are receiving chemotherapy.
- Conditions
- Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT00070382
- Testing
- darbepoetin alfa, epoetin alfa
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Jonsson Comprehensive Cancer Center
B-cell Acute Lymphocytic Leukemia
CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.
The purpose of this study is to infusion CD19 CAR-T cells to the patients with relapsed and refractory CD19+ B cell leukemia, to assess the safety and feasibility of this strategy.
- Trial name
- NCT03263208
- Testing
- Cyclophosphamide, Fludarabine, CD19 CAR-T
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Henan Cancer Hospital
Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
This phase II trial is studying the side effects and best dose of alemtuzumab when given together with fludarabine phosphate and total-body irradiation followed by cyclosporine and mycophenolate mofetil in treating patients who…
- Conditions
- Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Nasal Type Extranodal NK/T-cell Lymphoma
- Trial name
- NCT00118352
- Testing
- alemtuzumab, total-body irradiation, fludarabine phosphate
- Where
- 2 sites in United States, Italy
- Volunteers
- 12 people
- Sponsor
- Fred Hutchinson Cancer Center
Leukemia, Mucositis
Standard Chemotherapy with or Without Nelarabine or Rituximab in Treating Patients with Newly Diagnosed Acute Lymphoblastic Leukemia
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Leukemia, Mucositis, Oral Complications
- Trial name
- UKALL14 (NCT01085617)
- Testing
- palifermin, rituximab, cyclophosphamide
- Sponsor
- University College, London
Acute Lymphoblastic Leukemia
CD19 hsCAR-T for Refractory/Relapsed CD19+ B-ALL Patients
This Phase II study is to evaluate the efficacy and safety of a CD19-targeting humanized selective CAR-T (CD19 hsCAR-T) in refractory/relapsed CD19+ B-ALL leukemia patients who have no available curative treatment options, have a…
- Trial name
- NCT03902197
- Testing
- CD19 hsCAR-T
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- Xuanwu Hospital, Beijing
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
This phase Ib trial determines if samples from a patient's cancer can be tested to find combinations of drugs that provide clinical benefit for the kind of cancer the patient has.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Ann Arbor Stage III Hodgkin Lymphoma
- Trial name
- NCT03878524
- Testing
- Abemaciclib, Abiraterone, Afatinib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- OHSU Knight Cancer Institute
Acute Myeloid Leukemia, Hematologic Malignancies
Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies
This phase I trial studies the side effects and best dose of targeted marrow irradiation when given with fludarabine phosphate and busulfan before donor progenitor cell transplant in treating patients with hematologic…
- Conditions
- Acute Myeloid Leukemia, Hematologic Malignancies, Acute Lymphocytic Leukemia, Non Hodgkin Lymphoma
- Trial name
- NCT02129582
- Testing
- total marrow irradiation, fludarabine phosphate, busulfan
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Case Comprehensive Cancer Center
Leukemia, Lymphocytic, Chronic, B-Cell, B-Lymphocytic Leukemia, Chronic
Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias
Background: Chronic lymphocytic leukemia (CLL),small lymphocytic lymphoma (SLL) and B-cell acute lymphoblastic leukemia or lymphoma (ALL) are blood cancers that affect certain white blood cells.
- Conditions
- Leukemia, Lymphocytic, Chronic, B-Cell, B-Lymphocytic Leukemia, Chronic, B-Cell Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia
- Trial name
- NCT06364423
- Testing
- Autologous HuCD19 ( Anti-CD19)CAR T cells, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 132 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma
Combination Chemotherapy in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma Who Have Not Responded to Anthracycline-Containing Combination Chemotherapy
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00002488
- Testing
- cisplatin, cyclophosphamide, etoposide
- Where
- 2 sites in Canada
- Sponsor
- Ottawa Regional Cancer Centre
Leukemia, Lymphocytic, Acute, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell
CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCT
The clinical study of CART19 Cells treatment for MRD of B Cell Malignancies and then auto-HSCT
- Conditions
- Leukemia, Lymphocytic, Acute, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell
- Trial name
- NCT03685786
- Testing
- CART19 cell and auto-HSCT
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shenzhen Second People's Hospital
Leukemia, Lymphoma
Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Tretinoin may help hematologic cancer cells develop into normal white blood cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00006220
- Testing
- arsenic trioxide, tretinoin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Washington University School of Medicine
B-cell Acute Lymphoblastic Leukemia, Relapsed B-cell Acute Lymphoblastic Leukemia
Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients
This was a single arm, open-label, multi-center, phase II study to determine the efficacy and safety of an experimental therapy called CTL019 T-cells in pediatric patients with B-cell acute lymphoblastic leukemia, who were…
- Conditions
- B-cell Acute Lymphoblastic Leukemia, Relapsed B-cell Acute Lymphoblastic Leukemia, Refractory B-cell Acute Lymphoblastic Leukemia
- Trial name
- ENSIGN (NCT02228096)
- Testing
- CTL019 T-cells
- Where
- 13 sites in United States
- Volunteers
- 75 people
- Sponsor
- Novartis Pharmaceuticals
Lymphoma
SL-11047 in Treating Patients With Relapsed or Refractory Lymphoma
RATIONALE: Drugs used in chemotherapy, such as SL-11047, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00293488
- Testing
- polyamine analogue PG11047
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Progen Pharmaceuticals
Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma
Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies
This study uses a drug called dasatinib to produce an anti-cancer effect called large granular lymphocyte cellular expansion. Large granular lymphocytes are blood cells known as natural killer cells that remove cancer cells.
- Conditions
- Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Myeloid Leukemia, Multiple Myeloma
- Trial name
- NCT01643603
- Testing
- Dasatinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.